Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
Study Details
Study Description
Brief Summary
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the majority of whom with hybrid immunity of COVID-19 vaccination and COVID-19 breakthrough infection. Individuals aged 18 years and over, include the elderly over 60 years old or those with underlying diseases (history of underlying medical conditions diagnosed by a clinician, including hypertension, diabetes, heart disease, etc). The eligible participants with an interval ≥ 4 months after previous SARS-CoV-2 infection (or had never been infected) and ≥ 6 months from the first COVID-19 vaccine booster will be recruited. Participants who are not willing to receive the second booster but are consent to participate the surveillance for COVID-19, will be included as a blank control. Informed consent will be acquired from eligible participants. Other participants who are willing to receive the second booster and participate the surveillance for COVID-19, will be randomly allocated in a ratio of 1: k (k is the number of vaccine types) to the different investigational vaccines, stratified according to age and history of COVID-19 infection. The symptomatic COVID-19 cases will be reported and documented in both the investigational and control groups. The occurrence of serious adverse events within 6 months after vaccination will be observed. Moreover, blood and nasal mucosa samples will be collected on the day 0 before and day 14, month 3 and 6 after the booster vaccination in a subgroup for humoral, cellular and mucosal immunogenicity analysis.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Group 1 Subjects are assigned to receive one dose of intramuscularly administered Ad5-nCoV vaccine as the second booster. |
Biological: Intramuscularly administered Ad5-nCoV vaccine
This vaccine is produced by CanSino Biologics Inc.
|
Experimental: Group 2 Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster. |
Biological: Aerosolized Ad5-nCoV
This vaccine is produced by CanSino Biologics Inc.
|
Experimental: Group 3 Subjects are assigned to receive two doses of DelNS1-2019-nCoV-RBD-OPT1 vaccine as the second booster. |
Biological: DelNS1-2019-nCoV-RBD-OPT1
This vaccine is produced by Wantai Biopharmaceutical Company.
|
Experimental: Group 4 Subjects are assigned to receive one dose of SYS6006 vaccine as the second booster. |
Biological: SYS6006
This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
|
No Intervention: Group 5 Subjects are not assigned any vaccines served as a blank control. |
Outcome Measures
Primary Outcome Measures
- The incidence of COVID-19 from 14 days to 6 months after the booster immunization. [from 14 days to 6 months after the booster dose]
Secondary Outcome Measures
- The incidence of COVID-19 from 7 days to 6 months after the booster immunization. [from 7 days to 6 months the booster dose]
- The incidence of COVID-19 from 28 days to 6 months after the booster immunization. [from 28 days to 6 months the booster dose]
- The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 7 days to 6 months after the booster immunization. [from 7 days to 6 months the booster dose]
- The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 14 days to 6 months after the booster immunization. [from 14 days to 6 months the booster dose]
- The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 28 days to 6 months after the booster immunization. [from 28 days to 6 months the booster dose]
- The incidence of hospitalized COVID-19 from 7 days to 6 months after the booster immunization. [from 7 days to 6 months the booster dose]
- The incidence of hospitalized COVID-19 from 14 days to 6 months after the booster immunization. [from 14 days to 6 months the booster dose]
- The incidence of hospitalized COVID-19 from 28 days to 6 months after the booster immunization. [from 28 days to 6 months the booster dose]
- Geometric mean titer (GMT), Geometric mean fold increase (GMFI) and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on day 14 after the booster vaccination in the immunogenic subgroup. [On day 14 after the booster vaccination]
- GMT, GMFI and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on month 3 after the booster vaccination in the immunogenic subgroup. [On month 3 after the booster vaccination]
- GMT, GMFI and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on month 6 after the booster vaccination in the immunogenic subgroup. [On month 6 after the booster vaccination]
- GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on day 14 after the booster vaccination in the immunogenic subgroup. [On day 14 after the booster vaccination]
- GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on month 3 after the booster vaccination in the immunogenic subgroup. [On month 3 after the booster vaccination]
- GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on month 6 after the booster vaccination in the immunogenic subgroup. [On month 6 after the booster vaccination]
- GMT, GMFI and seroconversion of nasal specific IgA antibodies on day 14 after the booster vaccination in the immunogenic subgroup. [On day 14 after the booster vaccination]
- GMT, GMFI and seroconversion of nasal specific IgA antibodies on month 3 after the booster vaccination in the immunogenic subgroup. [On month 3 after the booster vaccination]
- GMT, GMFI and seroconversion of nasal specific IgA antibodies on month 6 after the booster vaccination in the immunogenic subgroup. [On month 6 after the booster vaccination]
- The incidence of serious adverse events within 6 months after the booster vaccination. [within 6 months after the booster dose]
Other Outcome Measures
- The effectiveness for preventing COVID-19 from 7 days after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. [on day 7 after the booster dose]
- The effectiveness for preventing COVID-19 from 14 days after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. [on day 14 after the booster dose]
- The effectiveness for preventing COVID-19 on day 28 after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. [on day 28 after the booster dose]
- Cross-neutralizing antibody levels against other variants on day 14 after the booster vaccination in the immunogenic subgroup. [On day 14 after the booster vaccination]
- Cross-neutralizing antibody levels against other variants on month 3 after the booster vaccination in the immunogenic subgroup. [On month 3 after the booster vaccination]
- Cross-neutralizing antibody levels against other variants on month 6 after the booster vaccination in the immunogenic subgroup. [On month 6 after the booster vaccination]
- Effectiveness and immunogenicity after the second booster immunization will be subgroup analyzed in the elderly over 60 years old and those with underlying diseases. [from 14 days to 6 months after the booster dose]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults aged 18 years and over, including the elderly over 60 years and those with underlying diseases.
-
Volunteers are able and willing to comply with the requirements of the clinical trial protocol and sign the informed consent form.
-
≥ 4 months from the last SARS-CoV-2 infection (or never been infected), and 6 months or more from the first booster immunization of the COVID-19 vaccine.
Exclusion Criteria:
-
Volunteers have suspected symptoms of COVID-19 when enrolled, such as dry throat, sore throat, cough, etc.
-
The COVID-19 Antigen Quick Test Kit is positive when volunteers are enrolled.
-
Fever, temperature > 37.0°C.
-
Have received a second COVID-19 vaccine booster immunization.
-
Have a history of serious adverse reactions related to the vaccine and/or have a history of severe allergic reactions to any component of the investigational vaccine (only applicable to the vaccine groups).
-
Pregnant or lactating women.
-
HIV infection, tuberculosis, low immunity caused by disease or long-term medication.
-
Acute disease or acute onset of chronic disease.
-
Epilepsy and other progressive neurological disorders.
-
Other situations that are not suitable for participating in this research, according to the judgment of the researcher.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Jiangsu Provincial Center for Disease Control and Prevention | Nanjing | Jiangsu | China | 210009 |
Sponsors and Collaborators
- Jiangsu Province Centers for Disease Control and Prevention
Investigators
- Principal Investigator: Jing-Xin Li, PhD, Jiangsu Provincial Center for Diseases Control and Prevention
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JSVCT178